comparemela.com
Home
Live Updates
Clinically Relevant Non Major Bleeding Compared - Breaking News
Pages:
Latest Breaking News On - Clinically relevant non major bleeding compared - Page 1 : comparemela.com
Anthos Therapeutics Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation
CAMBRIDGE, Mass. (BUSINESS WIRE) Nov 12, 2023
United states
United kingdom
Coll cardiol
Thromb haemost
Dan bloomfield
Anthos therapeutics inc
American heart association
Harvard medical school
Drug administration
Program in cancer associated thrombosis
Blackstone life sciences
Broad institute
Centers for disease
Primary endpoint
Clinically relevant non major bleeding compared
Atrial fibrillation
vimarsana © 2020. All Rights Reserved.